Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136902 | PMC |
| http://dx.doi.org/10.1093/neuonc/nou157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabinoids in glioblastoma multiforme-hype or hope?
Br J Cancer
April 2021
Department of Oncology, Cambridge University Hospitals NHS Foundation, Trust, Cambridge Biomedical Campus, Cambridge, UK.
Cannabis and its derivatives are being used increasingly by patients with cancer, including patients with glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy. Despite promising preclinical data suggesting potential anti-cancer effects for cannabinoids in GBM, clinical and safety data are lacking. This editorial will discuss a recent Phase 1b trial of nabiximols oromucosal spray in combination with dose-intense temozolomide in patients with recurrent GBM in the context of other relevant findings in this field.
View Article and Find Full Text PDFA phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Br J Cancer
April 2021
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Background: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.
Methods: Part 1 was open-label and Part 2 was randomised, double-blind, and placebo-controlled.
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
J Neurooncol
January 2021
Duke University, Durham, NC, USA.
Introduction: Glioblastoma (GBM) has a survival rate of around 2 years with aggressive current standard of care. While other tumors have responded favorably to trials combining immunotherapy and chemotherapy, GBM remains uniformly deadly with minimal increases in overall survival. GBM differ from others due to being isolated behind the blood brain barrier, increased heterogeneity and mutational burden, and immunosuppression from the brain environment and tumor itself.
View Article and Find Full Text PDFEnhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
ACS Appl Mater Interfaces
November 2019
Current treatment of recurrent glioblastoma multiforme (GBM) demands dose-intense temozolomide (TMZ), a prodrug of 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC), based on the spontaneous hydrolysis of TMZ at basic pH. However, how to control the activity of MTIC remains unknown, which poses a particular challenge to search a reliable MTIC receptor. We reported that copper, for the first time, is found to recognize and bind MTIC in the process of TMZ degradation, which means copper can play an important role in enhancing the bioavailability of MTIC derived from TMZ.
View Article and Find Full Text PDFContinuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Medicine (Baltimore)
March 2017
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, PR China Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA.
In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels. Previous studies demonstrated that cisplatin with the standard regimen of TMZ is active in patients suffering from recurrent GBM, generating a moderate level of toxicity. Also, continuous dose-intense TMZ is a helpful therapy for patients with recurrent GBM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!